Familial Hyperaldosteronism I–III

Abstract

Primary aldosteronism is the most frequent cause of secondary hypertension. Three variants of familial hyperaldosteronism are known today. Early onset hypertension and severe target organ damage are hallmarks of the heritable forms. The underlying gene defect has already been identified in familial hyperaldosteronism type I. In type II and III research is ongoing. A highly variable phenotype often precludes the discovery of the familial appearance of these syndromes. Taking a sound family history is extremely important to discover the Mendelian pattern of inheritance. The identification of affected families is highly rewarding because all variants can potentially be cured or at least specifically treated. Testing the relatives of an index patient sometimes even allows preemptive treatment. However, the availability of specific treatment options necessitates a solid differentiation between the three syndromes to avoid unnecessary medical therapy or surgery.

Key words

hyperaldosteronism - primary aldosteronism - familial hyperaldosteronism - Mendelian - adrenal glands - hypertension

References

• 1 Rossi GP, Seccia TM, Pessina AC. Primary aldosteronism – part I: prevalence, screening, and selection of cases for adrenal vein sampling.  J Nephrol. 2008;  21 447-454
• 2 Loffing J, Korbmacher C. Regulated sodium transport in the renal connecting tubule (CNT) via the epithelial sodium channel (ENaC).  Pflugers Arch. 2009;  458 111-135
• 3 Grossmann C, Gekle M. New aspects of rapid aldosterone signaling.  Mol Cell Endocrinol. 2009;  308 53-62
• 4 Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C. Intrarenal hemodynamics in primary aldosteronism before and after treatment.  J Clin Endocrinol Metab. 2009;  94 1191-1197
• 5 Staermose S, Marwick TH, Gordon RD, Cowley D, Dowling A, Stowasser M. Elevated serum interleukin 6 levels in normotensive individuals with familial hyperaldosteronism type 1.  Hypertension. 2009;  53 e31-e32
• 6 Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry.  J Clin Endocrinol Metab. 2009;  94 1125-1130
• 7 Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human Mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.  J Clin Endocrinol Metab. 2008;  93 3117-3123
• 8 Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young Jr. WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline.  J Clin Endocrinol Metab. 2008;  93 3266-3281
• 9 Quack I, Vonend O, Sellin L, Stegbauer J, Dekomien G, Rump LC. A tale of two patients with Mendelian hypertension.  Hypertension. 2008;  51 609-614
• 10 Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone.  Can Med Assoc J. 1966;  95 1109-1119
• 11 Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Finn WL, Krek AL. Clinical and pathological diversity of primary aldosteronism, including a new familial variety.  Clin Exp Pharmacol Physiol. 1991;  18 283-286
• 12 Lifton RP, Dluhy RG, Powers M, Ulick S, Lalouel JM. The molecular basis of glucocorticoid-remediable aldosteronism, a Mendelian cause of human hypertension.  Trans Assoc Am Physicians. 1992;  105 64-71
• 13 Stowasser M, Gordon RD, Tunny TJ, Klemm SA, Finn WL, Krek AL. Familial hyperaldosteronism type II: five families with a new variety of primary aldosteronism.  Clin Exp Pharmacol Physiol. 1992;  19 319-322
• 14 Mulatero P. A new form of hereditary primary aldosteronism: familial hyperaldosteronism type III.  J Clin Endocrinol Metab. 2008;  93 2972-2974
• 15 Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension.  Nature. 1992;  355 262-265
• 16 Miyahara K, Kawamoto T, Mitsuuchi Y, Toda K, Imura H, Gordon RD, Shizuta Y. The chimeric gene linked to glucocorticoid-suppressible hyperaldosteronism encodes a fused P-450 protein possessing aldosterone synthase activity.  Biochem Biophys Res Commun. 1992;  189 885-891
• 17 Stowasser M, Gartside MG, Taylor WL, Tunny TJ, Gordon RD. In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild-type genes.  J Clin Endocrinol Metab. 1997;  82 3670-3676
• 18 Ulick S, Chan CK, Gill Jr. JR, Gutkin M, Letcher L, Mantero F, New MI. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism.  J Clin Endocrinol Metab. 1990;  71 1151-1157
• 19 Willenberg HS, Schinner S, Ansurudeen I. New mechanisms to control aldosterone synthesis.  Horm Metab Res. 2008;  40 435-441
• 20 Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance.  J Clin Endocrinol Metab. 2000;  85 2160-2166
• 21 Gates LJ, MacConnachie AA, Lifton RP, Haites NE, Benjamin N. Variation of phenotype in patients with glucocorticoid remediable aldosteronism.  J Med Genet. 1996;  33 25-28
• 22 Vonend O, Altenhenne C, Buchner NJ, Dekomien G, Maser-Gluth C, Weiner SM, Sellin L, Hofebauer S, Epplen JT, Rump LC. A German family with glucocorticoid-remediable aldosteronism.  Nephrol Dial Transplant. 2007;  22 1123-1130
• 23 Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism.  J Clin Endocrinol Metab. 1997;  82 3570-3573
• 24 Malagon-Rogers M. Non-glucocorticoid-remediable aldosteronism in an infant with low-renin hypertension.  Pediatr Nephrol. 2004;  19 235-236
• 25 Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Treatment of familial hyperaldosteronism type I: only partial suppression of adrenocorticotropin required to correct hypertension.  J Clin Endocrinol Metab. 2000;  85 3313-3318
• 26 Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure.  Heart. 2002;  88 475-480
• 27 Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system.  Circulation. 1991;  83 1849-1865
• 28 Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.  J Clin Endocrinol Metab. 2005;  90 5070-5076
• 29 So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity.  J Hypertens. 2005;  23 1477-1484
• 30 Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22).  J Med Genet. 2000;  37 831-835
• 31 Stowasser M, Gordon RD. Primary aldosteronism: learning from the study of familial varieties.  J Hypertens. 2000;  18 1165-1176
• 32 Sukor N, Gordon RD, Ku YK, Jones M, Stowasser M. Role of unilateral adrenalectomy in bilateral primary aldosteronism: a 22-year single center experience.  J Clin Endocrinol Metab. 2009;  94 2437-2445
• 33 Newton-Cheh C, Guo CY, Gona P, Larson MG, Benjamin EJ, Wang TJ, Kathiresan S, O’Donnell CJ, Musone SL, Camargo AL, Drake JA, Levy D, Hirschhorn JN, Vasan RS. Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample.  Hypertension. 2007;  49 846-856
• 34 Buhler FR, Bolli P, Kiowski W, Erne P, Hulthen UL, Block LH. Renin profiling to select antihypertensive baseline drugs. Renin inhibitors for high-renin and calcium entry blockers for low-renin patients.  Am J Med. 1984;  77 36-42
• 35 Stowasser M, Gordon RD. Monogenic mineralocorticoid hypertension.  Best Pract Res Clin Endocrinol Metab. 2006;  20 401-420
• 36 Stowasser M, Gunasekera TG, Gordon RD. Familial varieties of primary aldosteronism.  Clin Exp Pharmacol Physiol. 2001;  28 1087-1090
• 37 Greco RG, Carroll JE, Morris DJ, Grekin RJ, Melby JC. Familial hyperaldosteronism, not suppressed by dexamethasone.  J Clin Endocrinol Metab. 1982;  55 1013-1016
• 38 Gagliardi L, Hotu C, Casey G, Braund WJ, Ling KH, Dodd T, Manavis J, Devitt PG, Cutfield R, Rudzki Z, Scott HS, Torpy DJ. Familial vasopressin-sensitive ACTH-independent macronodular adrenal hyperplasia (VPs-AIMAH): clinical studies of three kindreds.  Clin Endocrinol (Oxf). 2009;  70 883-891
• 39 Mulatero P, Bertello C, Verhovez A, Rossato D, Giraudo G, Mengozzi G, Limerutti G, Avenatti E, Tizzani D, Veglio F. Differential diagnosis of primary aldosteronism subtypes.  Curr Hypertens Rep. 2009;  11 217-223
• 40 Luft FC. Mendelian forms of human hypertension and mechanisms of disease.  Clin Med Res. 2003;  1 291-300
• 41 Martinez-Aguayo A, Fardella C. Genetics of hypertensive syndrome.  Horm Res. 2009;  71 253-259
• 42 Vonend O, Rump LC. Normokalemic primary hyperaldosteronism.  Dtsch Med Wochenschr. 2006;  131 H24-H27
• 43 Vonend O, Stegbauer J, Kokulinsky P, Adams S, Liermann D, Hahn K, Rump LC. Comparison of adrenal imaging and selective adrenal vein sampling in primary hyperaldosteronism.  Dtsch Med Wochenschr. 2007;  132 2436-2441

Correspondence